迪哲医药：舒沃哲全球注册临床研究入选2025年世界肺癌大会（WCLC）口头报告

Core Viewpoint - The company, Dige Medical, will present its newly developed targeted lung cancer drugs, ZEGFROVY (generic name: Shuwotini tablets) and a highly selective JAK1 inhibitor, Goliqitini capsules, at the 2025 World Lung Cancer Conference (WCLC) in Barcelona, Spain, from September 6 to 9, 2025 [1] Summary by Relevant Categories - Product Development - Dige Medical is set to showcase multiple latest research results on its innovative lung cancer therapies at an upcoming international conference [1] - The international multicenter registration clinical study "Wu-Kong1B" for ZEGFROVY has had its latest data selected for an oral presentation [1]